Price
No data yet.
Social Signal Score
Analyst Ratings
46 analystsRevenue
$84.75B+125.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Mauch
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Employees
- 49,000
- Beta
- 0.57
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.69
Financials
Revenue
$84.75B+125.6%Net Income
$763.52M+431.6%EBITDA
$1.41B+321.4%Free Cash Flow
$2.43B+102.0%EPS (diluted)
$3.94+525.4%Shares Outstanding (diluted)
193.94M-14.5%Operating Expenses
$2.13BCash & Debt
$2.82BReturn of Capital
$1.12BRevenue by Segment (annual)
$321.35BDividend per Share
$0.60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $321.33B | $1.55B | $8.02 |
| 2024 | $293.96B | $1.51B | $7.60 |
| 2023 | $262.17B | $1.75B | $8.62 |
| 2022 | $238.59B | $1.70B | $8.15 |
| 2021 | $213.99B | $1.54B | $7.48 |
| 2020 | $189.89B | $-3.40B | $-16.60 |
| 2019 | $179.59B | $855.37M | $4.07 |
| 2018 | $167.94B | $1.66B | $7.61 |
| 2017 | $153.14B | $414.48M | $1.67 |
| 2016 | $146.85B | $1.43B | $6.73 |
| 2015 | $135.96B | $-134.89M | $-0.62 |
| 2014 | $119.57B | $276.48M | $1.22 |
| 2013 | $87.96B | $433.71M | $1.88 |
| 2012 | $79.49B | $718.99M | $2.84 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from COR's reported EPS growth of 8.3% a year over 13 years.
- EPS in 5 years
- $11.95
- Implied price
- $465.91
- Return from $314.93
- 8.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $231.64 — -26.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 27 | 33 | 39 | 45 | 51 |
|---|---|---|---|---|---|
| -1.7% | -8.8% | -5.1% | -1.8% | 1.0% | 3.6% |
| 3.3% | -4.2% | -0.2% | 3.2% | 6.1% | 8.8% |
| 8.3% | 0.5% | 4.6% | 8.1% | 11.3% | 14.1% |
| 13.3% | 5.1% | 9.4% | 13.1% | 16.4% | 19.4% |
| 18.3% | 9.8% | 14.3% | 18.1% | 21.6% | 24.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
45-35.71%Social Signal Score
Mentions (21)
- Newsseekingalpha.com·5h ago·Neutral
Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow Cencora gets its prior buy rating reaffirmed again. Despite some market underperformance, specific business and macro fundamentals remain supportive. An investment-grade rating, positive operating cash flow, dividend safety, and an improved operating margin underscore the thesis.
View source ↗ - Newsbusinesswire.com·4d ago·Neutral
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.Participating in the conference call will be:Robert P. Mauch, President …
View source ↗ - News (RSS)businessinsider·5d ago·Positive
Worksport COR Energy System Now Available Through Amazon <i>New Amazon sales channel expands COR's sales reach beyond Worksport's web platform, to the world's largest retail market as Worksport targets growth in broader portable power, home backup and off-grid energy.</i> <strong id="dateline">WEST SENECA, NY / <a href='https://www.accessnewswire.com/' rel="noopener nofollow" target="_blank">ACCESS...
View source ↗ - News (RSS)investing·10d ago·Neutral
Cencora appoints former Ryder CEO to board of directors
View source ↗ - Newsbusinesswire.com·11d ago·Neutral
Cencora Elects Robert E. Sanchez to Its Board of Directors CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executive Chair of Ryder System, Inc., where he previously served as Chair and Chief Executive Officer until his retirement in March 2026. Prior to being appointed CEO in 2013, Mr. Sanchez spent two decades with Ryder serving in…
View source ↗ - Newszacks.com·12d ago·Positive
Here's Why Cencora (COR) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027 Cencora NYSE: COR executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses.
View source ↗ - Newsmarketbeat.com·15d ago·Positive
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference Cencora NYSE: COR executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.
View source ↗ - News (RSS)yahoo·16d ago·Neutral
Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?
View source ↗ - News (Alpha Vantage)Simply Wall Street·20d ago·Neutral
Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)? McKesson (MCK) recently increased its full-year EPS guidance, expecting 13-15% growth, and announced plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO in late 2027. The company is also acquiring Precision Medicine Group to enhance its oncology and biopharma services. While these developments signal operational strength and strategic expansion, the core investment narrative, including risks like dru
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·25d ago·Positive
Here's Why Cencora (COR) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·28d ago·Positive
Why Cencora (COR) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·31d ago·Negative
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
View source ↗ - Newszacks.com·31d ago·Neutral
Cencora Launches Cell and Gene Therapy Enablement for Health Systems COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
View source ↗ - Newszacks.com·32d ago·Positive
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
View source ↗ - News (RSS)investing·39d ago·Neutral
Cobram Estate FY26 slides: COR acquisition drives US growth amid profit decline
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity
View source ↗ - Newszacks.com·55d ago·Positive
Why Cencora (COR) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·56d ago·Positive
Here's Why Cencora (COR) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $4.54 per share
Typical surprise +3.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$4.48 vs $4.35beat
- Wed, May 6$4.75 vs $4.82miss
- Wed, Feb 4$4.08 vs $4.05beat
- Wed, Nov 5$3.84 vs $3.79beat
- Wed, Aug 6$4.00 vs $3.85beat
- Wed, May 7$4.42 vs $4.11beat
Estimates and results for COR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by COR officers and directors.
- Bought
- $2.3m
- Sold
- $15.1m
3 trades
12 trades
- Krikorian Lazarussold
- Greenberg Lon Rsold
- Krikorian Lazarussold
- Campbell Elizabeth Ssold
- Tyler Lauren Mbought
- Durcan Dermot Markbought
- Durcan Dermot Markbought
- Mauch Robert P.sold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Jun 22, 2026 (47d later)Sell$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Jun 22, 2026 (47d later)Sell$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed May 1, 2026 (39d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed May 1, 2026 (39d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed May 1, 2026 (31d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$50,001 - $100,000
- Greg Landsmanhouse · OH01 · disclosed Apr 9, 2025 (13d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Nov 14, 2024 (36d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Nov 14, 2024 (36d later)Buy$15,001 - $50,000
- Greg Landsmanhouse · OH01 · disclosed Aug 14, 2024 (77d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 20, 2024 (29d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 20, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (8d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (41d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (41d later)Sell$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.